MedTrace Logo

Prognostic Value Of Lymphocyte Count and Lymphocyte/ Monocyte Ratio in Patients With Hodgkin's Lymphoma

NCT04893538 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2022-03-03

No results posted yet for this study

Summary

This study is to assess the utility of using Absolute Lymphocyte count, Lymphocyte/Monocyte Ratio and International Prognostic Scote at diagnosis in Hodgkin's Lymphoma as a prognostic predictor of therapeutic response, overall survival and progression free survival

Conditions

Interventions

DIAGNOSTIC_TEST

First analysis: Lymphocyte count > or = 1500 cells per microlitre, second analysis: IPS < 3 and third analysis: Lymphocyte/Monocyte ratio > or = 2.9

Intravenous blood sampling from participants for complete blood count to obtain Lymphocyte count, Monocyte count and Lymphocyte/Monocyte Ratio and for plasma Albumin to obtain IPS

DIAGNOSTIC_TEST

First analysis: Lymphocyte count < 1500 cells per microlitre, second analysis: IPS > or = 3 and third analysis: Lymphocyte/Monocyte ratio < 2.9

Intravenous blood sampling from participants for complete blood count to obtain Lymphocyte count, Monocyte count and Lymphocyte/Monocyte Ratio and for plasma Albumin to obtain IPS

Sponsors & Collaborators

  • Tishreen University

    lead OTHER

Principal Investigators

  • FIRAS Hussain, Dr. · Tishreen University

  • Suzan Samra, Dr. · Tishreen University

  • Hasan Khalil · Tishreen University

Eligibility

Min Age
15 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-04
Primary Completion
2022-06-21
Completion
2022-07-01

Countries

  • Syria

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04893538 on ClinicalTrials.gov